Abstract

The lungs are constantly exposed to inhaled debris, allergens, pollutants, commensal or pathogenic microorganisms, and respiratory viruses. As a result, innate and adaptive immune responses in the respiratory tract are tightly regulated and are in continual flux between states of enhanced pathogen clearance, immune-modulation, and tissue repair. New single-cell-sequencing techniques are expanding our knowledge of airway cellular complexity and the nuanced connections between structural and immune cell compartments. Understanding these varied interactions is critical in treatment of human pulmonary disease and infections and in next-generation vaccine design. Here, we review the innate and adaptive immune responses in the lung and airways following infection and vaccination, with particular focus on influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The ongoing SARS-CoV-2 pandemic has put pulmonary research firmly into the global spotlight, challenging previously held notions of respiratory immunity and helping identify new populations at high risk for respiratory distress.

MeSH

Cells, Sars-Cov-2, Lung, Vaccines, Vaccination, Viruses, Immunity, Infections

Cited by

• Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies. Hum Vaccin Immunother, 2023
• Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization. Pharmaceutics, 2022
• Status and Challenges for Vaccination against Avian H9N2 Influenza Virus in China. Life (Basel), 2022
• Recent advances in respiratory immunization: A focus on COVID-19 vaccines. J Control Release, 2023
• Differential Immune Response Patterns Induced by Anionic and Cationic Lipid Adjuvants in Intranasal Anti-Influenza Immunization. Vaccines (Basel), 2024
• Enteroviruses Activate Cellular Innate Immune Responses Prior to Adaptive Immunity and Tropism Contributes to Severe Viral Pathogenesis. Microorganisms, 2025
• Targeting heptad repeats and fusion peptide: nanoparticle vaccine elicits mucosal immune response against SARS-CoV-2 variants. J Nanobiotechnology, 2025
• Multi-scenario photoacoustic endoscopy for in vivo functional imaging. Photoacoustics, 2025
• Oral administration of glycyrrhizic acid with intramuscular injection of foot-and-mouth disease vaccine enhances the adaptive immune system. Front Microbiol, 2025
• COVID-19 mRNA Vaccines Induce Robust Levels of IgG but Limited Amounts of IgA Within the Oronasopharynx of Young Children. J Infect Dis, 2024
• Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models. Virol Sin, 2023
• BEV 2C protein inhibits the NF-κB signalling pathway to promote viral replication by targeting IKBKB and p65. Vet Res, 2025
• A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination. Vaccines (Basel), 2022
• Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study. Biomedicines, 2022
• A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. Vaccine, 2023
• Exploring the standardization of human nasal antibody measurements. Emerg Microbes Infect, 2025
• Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA. Front Immunol, 2025
• Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis. Front Microbiol, 2023
• The potential role of ocular and otolaryngological mucus proteins in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Med, 2024
• Mucosal immunity and vaccination strategies: current insights and future perspectives. Mol Biomed, 2025